One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Last-Mile Logistics of Covid Vaccination — The Role of Health Care Organizations
Thomas H. Lee, M.D., and Alice H. Chen, M.D., M.P.H.
doi : 10.1056/NEJMp2100574
N Engl J Med 2021; 384:685-687
Telemedicine and Medical Licensure — Potential Paths for Reform
Ateev Mehrotra, M.D., Alok Nimgaonkar, B.A., and Barak Richman, J.D., Ph.D.
doi : 10.1056/NEJMp2031608
N Engl J Med 2021; 384:687-690
The Inequity of Isolation
Simone Vais, M.D.
doi : 10.1056/NEJMp2029725
N Engl J Med 2021; 384:690-691
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group*
doi : 10.1056/NEJMoa2021436
N Engl J Med 2021; 384:693-704
Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, M.D., Larry D. Anderson, Jr., M.D., Ph.D., Nina Shah, M.D., Deepu Madduri, M.D., Jes?s Berdeja, M.D., Sagar Lonial, M.D., Noopur Raje, M.D., Yi Lin, M.D., Ph.D., David Siegel, M.D., Ph.D., Albert Oriol, M.D., Philippe Moreau, M.D., Ibrahim Yakoub-Agha, M.D., Ph.D., Michel Delforge, M.D., Michele Cavo, M.D., Hermann Einsele, M.D., Hartmut Goldschmidt, M.D., Katja Weisel, M.D., Alessandro Rambaldi, M.D., Donna Reece, M.D., Fabio Petrocca, M.D., Monica Massaro, M.P.H., Jamie N. Connarn, Ph.D., Shari Kaiser, Ph.D., Payal Patel, Ph.D., Liping Huang, Ph.D., Timothy B. Campbell, M.D., Ph.D., Kristen Hege, M.D., and Jes?s San-Miguel, M.D., Ph.D.
doi : 10.1056/NEJMoa2024850
N Engl J Med 2021; 384:705-716
Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
Stephen K. Brannan, M.D., Sharon Sawchak, R.N., Andrew C. Miller, Ph.D., Jeffrey A. Lieberman, M.D., Steven M. Paul, M.D., and Alan Breier, M.D.
doi : 10.1056/NEJMoa2017015
N Engl J Med 2021; 384:717-726
The muscarinic receptor agonist xanomeline has antipsychotic properties and is devoid of dopamine receptor–blocking activity but causes cholinergic adverse events. Trospium is a peripherally restricted muscarinic receptor antagonist that reduces peripheral cholinergic effects of xanomeline. The efficacy and safety of combined xanomeline and trospium in patients with schizophrenia are unknown.
?-Thalassemias
Ali T. Taher, M.D., Ph.D., Khaled M. Musallam, M.D., Ph.D., and M. Domenica Cappellini, M.D.
doi : 10.1056/NEJMra2021838
N Engl J Med 2021; 384:727-743
Gum Hypertrophy from Cyclosporine
Bina S. Menon, M.R.C.P., and Kok-Hoi Teh, M.R.C.P.C.H.
doi : 10.1056/NEJMicm2026082
N Engl J Med 2021; 384:744
A Large Abdominal Mass
Shu Hui Neo, M.B., B.S., and Lui Shiong Lee, M.B., B.S.
doi : 10.1056/NEJMicm2026560
N Engl J Med 2021; 384:e24
Case 6-2021: A 65-Year-Old Man with Eye Pain and Decreased Vision
Marc A. Bouffard, M.D., Bart K. Chwalisz, M.D., Javier M. Romero, M.D., Isabel C. Arrillaga-Romany, M.D., and Lucas R. Massoth, M.D.
doi : 10.1056/NEJMcpc2027089
N Engl J Med 2021; 384:745-753
Research in the Context of a Pandemic
H. Clifford Lane, M.D., and Anthony S. Fauci, M.D.
doi : 10.1056/NEJMe2024638
N Engl J Med 2021; 384:755-757
The RECOVERY Platform
Sharon-Lise T. Normand, Ph.D.
doi : 10.1056/NEJMe2025674
N Engl J Med 2021; 384:757-758
Audio Interview: The Real-World Effectiveness of Covid-19 Vaccination
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2103272
N Engl J Med 2021; 384:e40
CMS Innovation Center at 10 Years — Progress and Lessons Learned
Brad Smith, M.Phil.
doi : 10.1056/NEJMsb2031138
N Engl J Med 2021; 384:759-764
STING-Induced Inflammation — A Novel Therapeutic Target in ALS?
Philip Van Damme, M.D., Ph.D., and Wim Robberecht, M.D., Ph.D.
doi : 10.1056/NEJMcibr2031048
N Engl J Med 2021; 384:765-767
How Structural Racism Works — Racist Policies as a Root Cause of U.S. Racial Health Inequities
Zinzi D. Bailey, Sc.D., M.S.P.H., Justin M. Feldman, Sc.D., and Mary T. Bassett, M.D., M.P.H.
doi : 10.1056/NEJMms2025396
N Engl J Med 2021; 384:768-773
Injuries from Less-Lethal Weapons during the George Floyd Protests in Minneapolis
doi : 10.1056/NEJMc2032052
N Engl J Med 2021; 384:774-775
Colchicine in Patients with Chronic Coronary Disease
doi : 10.1056/NEJMc2034992
N Engl J Med 2021; 384:776-779
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
doi : 10.1056/NEJMc2035798
N Engl J Med 2021; 384:e26
The Purdue Pharma Opioid Settlement — Accountability, or Just the Cost of Doing Business?
doi : 10.1056/NEJMx210001
N Engl J Med 2021; 384:782
